Hospital

The Mylight phase 3 trial confirmed that there was no clinically meaningful differences between aflibercept and its reference biologic, Eylea, for patients with wet macular degeneration.

The combination regimen showed positive progression-free survival results among patients with HER2-positive breast cancer in the phase 3 HER2CLIMB-02 trial, but overall survival data have yet to mature.

Researchers recommended less restrictive policy regarding telepharmacies to improve access to medications and pharmacists, while ultimately improving outcomes and adherence to treatment regimens.

Melphalan/hepatic delivery system (Hepzato Kit; Delcath Systems Inc) is currently the only liver-directed therapy approved by the FDA for the treatment of netastatic uveal melanoma and percutaneous hepatic perfusion.

Topics discussed include care workflow, app functionalities, problems and disadvantages, and benefits for HIV experts.

Pharmacies brace for a double wave of DIR fees while paddling against profit struggles. Enter Pharmacy AI: a transformative vehicle to navigate stormy waters, enhance efficiency, and prioritize patient care.

Unexpectedly, a study found that more than 70% of cancer survivors were current drinkers, indicating the need for intervention and strategies to reduce harmful drinking habits.

Intravenous immunoglobulin was found to be the most effective immunotherapy in preventing relapses after treatment with steroids in pediatric patients.

Key study finding shows associations between the beat frequency in the rhythmic stimulus in the frontal left sites of infant brains and pathways related to brain modulation and nucleotide levels.

Prior to this study, anti-platelet factor 4 disorder was thought to be caused by exposure to heparin or autoimmune conditions.

Stakeholders need to convene honest, actionable discussions about the challenges and the safeguards needed to address appropriate use of artificial intelligence in health care.

A dose of 900 mg per day of gabapentin prior to spine surgery was associated with the lowest pain score among all studied dosages.

Study investigators suggest that there is a higher prevalence of pain and treatment needs in this small population.

Pharmacists will have the opportunity to use their knowledge of biosimilars to reinforce their benefits, safety, and efficacy.

Although not a traditional at-risk group for severe respiratory syncytial virus complications, pregnant patients should be aware of the possibility of infection and be educated on proper prevention procedures.

A panel released recommendations in accordance with decades of a changing landscape in acetaminophen poisoning and due to an absence of agreed upon guidelines in the space.

Elranatamab-bcmm (Elrexfio; Pfizer) is a BCMA-CD3-targeted bispecific antibody approved for adults with relapsed or refractory multiple myeloma who were previously administered at least 4 lines of therapy that included a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

The growing awareness in health care of the challenges associated with proper dosing of anticoagulants such as heparin has inspired the emerging field of anticoagulation stewardship.

Prior studies had produced conflicting results on whether the pandemic positively or negatively impacted health care-associated C. difficile infections, yet the results of this current study indicate the pandemic played a limited role.

Study authors note that additional research is necessary to confirm findings and identify biological pathways of associations between sweetened beverages and diseases of the liver.

Research shows a substantial difference between overall deaths of men and women at 43% and 28.2%, respectively, from cardiovascular disease associated with particulate matter.

Niraparib and abiraterone acetate (Akeega; Janssen Pharmaceutical Companies of Johnson & Johnson) is the first-and-only dual action tablet that combines a PARP inhibitor with abiraterone acetate administered with prednisone.

Many studies with a stated goal of advancing child health care in administratively-defined minors have no clinical value and may even harm young patients.

Advancements in the development of amyloid-targeting monoclonal antibodies show promise for treating Alzheimer disease, but there have been concerns around cost, adverse reactions, and inequity of care for marginalized patients.

Unexpectedly, the highest increases in delirium compared to projections were in the 66 to 74 years of age group, which could have important personal and societal repercussions, such as earlier development of dementia.

New standards from the National Council for Prescription Drug Programs could drive changes that improve patient safety by optimizing drug therapy to reduce the risk of harm and improve health and well-being before a medication is dispensed.

In the COLUMBUS study, the FDA requested that the investigators evaluate the contribution of binimetinib while maintaining the same dosage of encorafenib at 300 mg to confirm the benefits of the combination.

Although SB5 is an effective treatment for plaque psoriasis, it is recommended that patients consider the potential risks and adverse effects.